Key facts
- This page summarizes Brian Daniel Webster's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Jul 2026, 17:48.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Sale
Sale
Sale
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.
Footnote F2
The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
Footnote F3
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.45 to $22.44. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Footnote F4
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.45 to $23.00. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Footnote F5
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.49 to $24.10. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
SEC remarks
President and Chief Executive Officer